novo nordisk's wegovy reduces cardiovascular risk more than lilly's tirzepatide Weight-loss drug produces 'largest benefit ever seen' for patients with most common form of heart failure, trial finds Wegovy® Demonstrates Superior Cardiovascular Benefit

Pfizer has struck a $2 billion deal with YaoPharma to develop and commercialize a phase 1 small-molecule GLP-1 receptor agonist for chronic weight management [1]

f DSGVO auf Grundlage unseres berechtigten Interesses an der statistischen Analyse des Nutzerverhaltens zu Optimierungs- und Marketingzwecken

H., Kuravi, S

Providers who genuinely connect with their patients can better empower them to take an active role in their care and incorporate healthy lifestyle changes

Hormonal shifts: Thyroid imbalances, pregnancy, menopause, and PCOS push more follicles into resting phases prematurely

A subsequent cross-sectional study by Yekta et al